Alexis Borisy
Partner @ Third Rock Ventures
Boston, United States
Alexis Borisy is a Series A investor at Third Rock Ventures in Boston focused on Biotechnology and Health Care. Alexis Borisy is the Co-Founder and Chairman of Curie.Bio. He previously worked at Thrive Earlier Detection Corp. as a Board Of Directors. Alexis Borisy attended Harvard University.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 21%
Last updated:
For AI agents: llms.txt
Industries Alexis Borisy invests in
Stages Alexis Borisy invests in
Countries Alexis Borisy invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 6 (43%)
- Health Care 5 (36%)
- Genetics 4 (29%)
- Medical 3 (21%)
- Life Science 1 (7%)
Stage
- Series A 5 (36%)
- Series B 5 (36%)
- Series C 2 (14%)
- Private Equity 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Celsius Therapeutics develop life-changing medicines and discover critical biomarkers for patient care by better understanding the cellular ecosystem of diseases through Single Cell Genomics and Machine Learning. | $83M / Series B / Mar 24, 2022 | ||
| Insitro is an operator of a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients.The company uses state-of-the-art technologies from bioengineering enabling it to generate high-throughput, functional genomic data setsand aligning them with patient data via novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.In 2018, Daphne Koller established Insitro in South San Francisco, California.. | $400M / Series C / Mar 15, 2021 | ||
| Insitro is an operator of a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients.The company uses state-of-the-art technologies from bioengineering enabling it to generate high-throughput, functional genomic data setsand aligning them with patient data via novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.In 2018, Daphne Koller established Insitro in South San Francisco, California.. | $143M / Series B / May 26, 2020 | ||
| Insitro is an operator of a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients.The company uses state-of-the-art technologies from bioengineering enabling it to generate high-throughput, functional genomic data setsand aligning them with patient data via novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.In 2018, Daphne Koller established Insitro in South San Francisco, California.. | $100M / Series A / Apr 16, 2019 | ||
| Celsius Therapeutics develop life-changing medicines and discover critical biomarkers for patient care by better understanding the cellular ecosystem of diseases through Single Cell Genomics and Machine Learning. | $65M / Series A / May 15, 2018 | ||
| Insitro is an operator of a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients.The company uses state-of-the-art technologies from bioengineering enabling it to generate high-throughput, functional genomic data setsand aligning them with patient data via novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.In 2018, Daphne Koller established Insitro in South San Francisco, California.. | $100M / Series A / May 02, 2018 | ||
| Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translateearly findings into viable human therapeutic products.Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado. | $120M / Series B / Aug 10, 2015 | ||
| Blueprint Medicines develops targeted therapies for cancer and blood disorders, focusing on precision medicine. The company utilizes genetic insights to design treatments tailored to individual patient needs. Their portfolio includes products aimed at specific mutations and conditions, enhancing treatment options for patients with various types ofcancer and hematologic diseases. Blueprint Medicines collaborates with healthcare providers to ensure that their therapies are accessible and effectively integrated into patient care. Through ongoing research and development, the company aims to expand its offerings and address unmet medical needs in oncology and hematology. | $50M / Series C / Nov 12, 2014 | ||
| Blueprint Medicines develops targeted therapies for cancer and blood disorders, focusing on precision medicine. The company utilizes genetic insights to design treatments tailored to individual patient needs. Their portfolio includes products aimed at specific mutations and conditions, enhancing treatment options for patients with various types ofcancer and hematologic diseases. Blueprint Medicines collaborates with healthcare providers to ensure that their therapies are accessible and effectively integrated into patient care. Through ongoing research and development, the company aims to expand its offerings and address unmet medical needs in oncology and hematology. | $25M / Series B / Jan 07, 2014 | ||
| Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translateearly findings into viable human therapeutic products.Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado. | $43M / Series A / Nov 25, 2013 | ||
| See all 14 investments → | |||
Co-Investors
About Third Rock Ventures
Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.
Third Rock Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Cary Pfeffer
Partner
|
|||
|
Jeff Tong
Partner
|
|||
Jigar Raythatha
Partner
|
|||
Mark Levin
Partner
|
|||
Reid Huber
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alexis Borisy invest in?
Alexis Borisy invests primarily in Biotechnology, Health Care and Genetics startups, most often at Series A and Series B stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Alexis Borisy?
Public channels for Alexis Borisy include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Alexis Borisy last invest?
The most recent investment recorded for Alexis Borisy closed in Mar 2022. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
